Boston Scientific Co. (NYSE:BSX) EVP Kevin J. Ballinger sold 28,864 shares of the business’s stock in a transaction that occurred on Wednesday, May 17th. The stock was sold at an average price of $26.14, for a total value of $754,504.96. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Shares of Boston Scientific Co. (NYSE:BSX) traded up 1.03% during midday trading on Friday, reaching $26.41. The company’s stock had a trading volume of 7,924,635 shares. The stock has a market capitalization of $36.17 billion, a PE ratio of 84.65 and a beta of 1.06. Boston Scientific Co. has a 12 month low of $19.67 and a 12 month high of $26.76. The stock’s 50 day moving average is $25.58 and its 200 day moving average is $23.71.
Boston Scientific (NYSE:BSX) last announced its earnings results on Thursday, April 27th. The medical equipment provider reported $0.29 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.30 by $0.01. Boston Scientific had a return on equity of 23.70% and a net margin of 4.14%. The firm had revenue of $2.16 billion for the quarter, compared to the consensus estimate of $2.08 billion. During the same period in the previous year, the firm earned $0.28 EPS. Boston Scientific’s revenue for the quarter was up 10.0% on a year-over-year basis. On average, analysts forecast that Boston Scientific Co. will post $1.25 EPS for the current fiscal year.
Several equities analysts have issued reports on the company. Goldman Sachs Group Inc assumed coverage on Boston Scientific in a research report on Tuesday. They set a “neutral” rating and a $28.00 target price on the stock. Zacks Investment Research upgraded Boston Scientific from a “sell” rating to a “hold” rating in a research report on Monday, May 1st. Stifel Nicolaus boosted their target price on Boston Scientific from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, April 28th. Cowen and Company boosted their target price on Boston Scientific from $29.00 to $31.00 and gave the stock an “outperform” rating in a research report on Friday, April 28th. Finally, Evercore ISI boosted their target price on Boston Scientific from $26.50 to $28.50 and gave the stock an “outperform” rating in a research report on Friday, April 28th. Six research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $27.83.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Synovus Financial Corp acquired a new position in Boston Scientific during the third quarter valued at about $102,000. Quadrant Capital Group LLC raised its position in Boston Scientific by 10.3% in the first quarter. Quadrant Capital Group LLC now owns 5,201 shares of the medical equipment provider’s stock valued at $122,000 after buying an additional 487 shares during the period. Bronfman E.L. Rothschild L.P. raised its position in Boston Scientific by 7.2% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 5,041 shares of the medical equipment provider’s stock valued at $125,000 after buying an additional 338 shares during the period. Guardian Life Insurance Co. of America raised its position in Boston Scientific by 0.9% in the first quarter. Guardian Life Insurance Co. of America now owns 5,266 shares of the medical equipment provider’s stock valued at $131,000 after buying an additional 49 shares during the period. Finally, JNBA Financial Advisors raised its position in Boston Scientific by 467.9% in the fourth quarter. JNBA Financial Advisors now owns 7,298 shares of the medical equipment provider’s stock valued at $158,000 after buying an additional 6,013 shares during the period. Hedge funds and other institutional investors own 91.70% of the company’s stock.
Boston Scientific Company Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Co. and related companies with MarketBeat.com's FREE daily email newsletter.